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Summary Three hundred and sixty-seven women presenting to the Breast Unit at Guy's Hospital between 1975 and 1990 whose first distant metastasis was in the skeleton were identified and the influence of a number of patient and tumour characteristics on the development and subsequent prognosis of bone metastases was assessed.
One hundred and thirty-nine women had disease that remained clinically confined to the skeleton. They were more likely to be older, with lobular carcinoma and to have presented initially with little or no axillary lymph node involvement. The 228 women who subsequently developed disease at extra-osseus sites were more likely to have poorly differentiated ductal tumours and heavy lymph node involvement at primary diagnosis.
On multivariate analysis, the clinical and pathological factors of greatest prognostic importance for survival after the development of bone metastases were histological grade (P = < 0.0001), oestrogen receptor status (P = < 0.0001), bone disease at initial presentation (P= < 0.0001), disease-free interval (P= 0.002) and age (P= 0.006).
To enable a rational cost-effective use of bisphosphonates in metastatic bone disease, selection of patients with relatively indolent, bone-only disease for bisphosphonate therapy (as defined in this study) should be compared with the current licensed recommendation of unselected treatment for all patients with lytic bone metastases.
Bone metastases are frequent in advanced breast cancer and often contribute to the cause of death. Like breast cancer affecting other organs, metastatic bone disease has an extremely variable prognosis. The median survival is 2 years with 20% of patients remaining alive for 5 years after first recurrence in bone (Coleman and Rubens, 1987) . In addition, a significant proportion of patients appear clinically to have disease confined to the skeleton, and these women die of the complications of metastatic bone disease, namely immobility, pathological fractures, hypercalcaemia of malignancy and bone marrow failure, with no evidence clinically of involvement at other metastatic sites.
With the development of bisphosphonates as specific treatments for metastatic bone disease (Body et al, 1996) , there is increased interest in identifying those patients who are most likely to benefit from bisphosphonate treatment. In addition, if prophylactic use of bisphosphonates proves able to influence the development of bone metastases, it will be important to identify those patients at greatest risk of bone involvement, particularly in isolation from other metastatic disease, so that treatment can be targeted rationally.
In this study, we have reviewed the clinical and tumour characteristics of patients developing first recurrence of breast cancer in bone and identified prognostic factors that predict for both survival and/or subsequent spread to other metastatic sites.
PATIENTS AND METHODS
Three hundred and sixty-seven women presenting to the Breast Unit at Guy's Hospital between 1975 and 1990 whose first distant metastasis was in the skeleton were identified from the database. This database contains information on patient and tumour characteristics, a number of biological features, such as histological grade and steroid receptor status, details of metastatic involvement, response to treatment and survival.
Histological grading was performed almost entirely by one pathologist using the Bloom and Richardson grading (Bloom and Richardson, 1957) . Oestrogen and progesterone receptor status were measured during this time period using the dextran-coated charcoal method as described by King et al (1979) .
Clinical management followed consistent guidelines throughout the study period. All patients were assessed clinically on a regular basis, and bone scans, radiographs of regions of increased uptake and chest radiographs were performed whenever a change in systemic therapy was indicated. Routine liver scans were not performed unless there was clinical evidence of hepatomegaly or disordered serum tests of liver function. Brain scans were only performed for investigation of specific symptoms.
Endocrine therapy has been the initial treatment of choice for symptomatic advanced breast cancer. For premenopausal patients, this has been ovarian ablation ± prednisolone and, for postmenopausal patients, tamoxifen ± prednisolone. The only exceptions to this policy have been those known to have oestrogenand progesterone-negative tumours or the occasional patient with For the purpose of statistical analysis, survival curves were calculated using the method of Kaplan and Meier (1958) , with _n = 356 significance determined using the log-rank test (Peto et al, 1977) .
Multivariate survival analysis was performed using Cox's propor- tional hazards model (Cox, 1972 Time (years) Figure 5 Survival after first recurrence in the skeleton according to subsequent development of non-osseus metastases (B+) or disease confined to the skeleton (Bo). Yes, bone and other subsequent sites (B+); no, bone only (BO) outside the skeleton (B+). There was no difference in oestrogen or progesterone receptor status between BO and B+ patients. Figure 1 shows the time from diagnosis of breast cancer to first recurrence in the skeleton with a median time to Table 2 shows the frequency of major skeletal involvement. Hypercalcaemia and pz a long bone (principally femora or humeri) M complications, each occurring in a little ur There was no significant difference in the fr tions between patients with Bo or those with The probability of survival after develol was assessed according to the available biological characteristics using the Cox model. The variables tested along with both variate prognostic significance are shown in Patients having bone disease coincident M tation of their breast cancer [disease-free in 40] had a better survival than other patients. more marked on multivariate than univariat the influence of additional features expected nosis, notably worse histology, older age a interval (by definition). Histological grade a most significant prognostic factor with gi tumours or lobular carcinoma having the be III the worst survival (Figure 2 ). Oestrogen also predicted survival with ER-positive pati than those who were ER-negative (Figure 3) Survival from the diagnosis of bone metas disease-free interval from breast cancer di Figure 4 . Patients with a disease-free interva (n = 112) had a better survival than thosi interval of less than 3 years (n = 243, P = 0.0 development of bone metastases was premenopausal patients then for those wor peri-menopausal or post-menopausal (P = 0.' Patients with Bo disease had a median compared with 1.6 years in B+ patients (P = I difference was most apparent for those X developing metastases in the liver (Figure 6) The stepwise multivariate analysis was re patients. The factors predicting for survival the same in both groups, although because o: some factors now just failed to reach st, However, in the Bo group, all relative risks w that the prognostic factors are more predic bone-only disease.
DISCUSSION Chi= 19.18
Patients with bone metastases may experience a protracted clinical P < 0.001 course as a result of both the indolent nature of the disease and the remissions obtained by systemic treatment. Patients with disease remaining confined to the skeleton (BO) have a better prognosis than the patients who develop metastatic disease at non-osseus sites (B+). Elderly post-menopausal patients were more likely to have Bo disease than those who were pre-or peri-menopausal. Disease remaining confined to the skeleton was more likely with lobular No n= 259 carcinomas and less so with poorly differentiated grade III ductal 10 12 tumours. Similar to previous studies (Coleman and Rubens, 1987; Koenders et al, 1991) , oestrogen receptor status predicted for the development of bone metastases, but it was not important in determining the patients in whom metastatic disease would remain clinton according to ically confined to the skeleton. In recent years, a number of studies have indicated a relationship between tumour expression of parathyroid hormone-related peptide (PTHrP) and the development of bone metastases (Bundred et al, 1992; Vargas et al, 1992) . complications from Unfortunately, it was not possible to retrospectively assess the athological fracture of tumours in this series for PTHrP expression. vere the most frequent
The observation that tumours with little or no axillary lymph ider 20% of patients.
node involvement are more likely to remain confined to the *equency of complicaskeleton is interesting. Bone metastases are typically distributed to B+ disease patterns. 1 of more than 3 years a minority of patients, prompting speculation, particularly in those e with a disease-free with disease apparently confined to the skeleton, of their mode of 02). Survival after the death. Presumably immobility due to pain and large doses of slightly better for narcotic analgesics predispose the patient to infection, particularly nen who were either pneumonia. 002).
The bisphosphonates, notably intravenous pamidronate (Purohit survival of 2.1 years et al, 1994; Conte et al, 1996; Hortobagyi et al, 1996) and to a lesser 0.001, Figure 5 ). This extent oral clodronate (Paterson et al, 1993) , have been shown to patients subsequently relieve pain, reduce analgesic consumption and improve mobility. As a result, they could be reasonably expected, particularly in those Xpeated for Bo and B+ with bone-only disease, to have a positive impact on survival as well Lremained essentially as quality of life. To date, the preliminary analyses of placebof the smaller numbers controlled studies have failed to show any influence of bisphosphoatistical significance.
nate treatment on survival (Paterson et al, 1993; Hortobagyi et al, iere higher, indicating 1996) . However, none of the randomized studies conducted to date vtive in patients with have attempted to select those patients who are most likely to benefit from bisphosphonates, notably those with bone-only disease.
Both pamidronate and clodronate are relatively expensive drugs and because of increasing pressure on health care budgets, despite the impressive clinical trial results, cannot be immediately incorporated into routine long-term supportive treatment for all patients with bone metastases. Until better biological or biochemical predictors of response to bisphosphonates are available (Vinholes et al, 1996) , we would suggest that only those patients with a relatively good prognosis should be selected for long-term bisphosphonate treatment. On the basis of the data presented, this would include bone-only disease after a long DFI from either a steroid receptor-positive and/or favourable histology tumour. Support for such selection does however require analysis of a larger database of patients, with recording of skeletal events and their subsequent treatment. It is hoped that the recent randomized trials of pamidronate (Hortobagyi et al, 1996; Lipton et al, 1997) , which included the collection of data for economic evaluation as well as meticulous recording of skeletal events, will use these data for analysis not only by treatment group but also according to prognostic factors, including those identified in this study, to assess whether the selective use of bisphosphonates improves the cost-effectiveness of this new treatment modality. In addition, and possibly of greater value, might be the ability to specify those patients at most risk of developing serious complications of bone metastases, particularly pathological fracture and hypercalcaemia, but the relevant predictors remain to be identified.
